Introduction {#section5-1179556517701118}
============

Indirect (unconjugated) hyperbilirubinemia, which is seen in 60% to 80% of newborns in the first days of life, may be one of the first signs of a serious bacterial infection.^[@bibr1-1179556517701118]^ This type of jaundice may reportedly be an important and even the first presenting sign of urinary tract infection (UTI).^[@bibr2-1179556517701118]^ The physiopathologic relationship between neonatal jaundice and UTI has always gained much interest and recently been investigated in various studies. However, this relationship has been preferably studied in newborns with late (≥8 days) jaundice,^[@bibr3-1179556517701118][@bibr4-1179556517701118][@bibr5-1179556517701118]--[@bibr6-1179556517701118]^ prolonged jaundice (≥15 days),^[@bibr5-1179556517701118],[@bibr7-1179556517701118][@bibr8-1179556517701118]--[@bibr9-1179556517701118]^ or conjugated hyperbilirubinemia,^[@bibr5-1179556517701118]^ and only few studies among newborns with early (≤7 days) jaundice have been conducted.^[@bibr2-1179556517701118],[@bibr10-1179556517701118],[@bibr11-1179556517701118]^ Currently, authorized international institutions, such as American Academy of Pediatrics, do not recommend investigation of UTI with urinalysis or urine culture as part of investigations for the etiology of either early or late/prolonged neonatal jaundice.^[@bibr12-1179556517701118]^

In this study, etiologic role, prevalence, demographic, and response-to-treatment characteristics of UTI among neonates, its relationship with significant neonatal hyperbilirubinemia, and abnormalities of the urinary system were studied in a prospective investigation in early (≤10 days) idiopathic neonatal jaundice in which all other etiologic factors of neonatal hyperbilirubinemia were ruled out.

Patients and Methods {#section6-1179556517701118}
====================

This study was conducted at the Division of Neonatology, Department of Pediatrics of Ufuk University Faculty of Medicine between June 2015 and August 2016. All newborns who were diagnosed with significant hyperbilirubinemia and required phototherapy treatment were included in the study. With the aim to determine whether UTI was the cause of pathologic jaundice, urine samples for microscopic and bacteriologic examination were obtained via bladder catheterization in all cases.

The diagnosis of significant hyperbilirubinemia was made considering gestational and postnatal age and risk factors of the newborns,^[@bibr12-1179556517701118],[@bibr13-1179556517701118]^ and these cases were put on phototherapy. Late preterm, early term, and term newborns were included in the study, and newborns with a gestational age of less than 35 weeks were not included as the prematurity itself is a major risk factor in the etiology of hyperbilirubinemia.

As the primary aim of the study was to determine whether UTI itself was the leading cause in the etiology of significant hyperbilirubinemia, newborns with isoimmunization (ABO, Rh, or subgroup incompatibilities), direct Coombs test positivity, findings of hemolysis on blood smear (anisocytosis, spherocytosis, polychromasia, poikilocytosis), anemia, reticulocytosis, and/or glucose-6-phosphate dehydrogenase deficiency were excluded from the study. Other exclusion criteria were the presence of any major congenital anomaly, respiratory distress, and clinical or culture-proven sepsis.

The study was conducted according to clinical practice guidelines and approved by the local ethics committee. Informed consent was obtained from any parents of each patient. Parents were questioned in detail regarding their baby's clinical signs and symptoms other than jaundice, such as fever, lethargy, irritability, diarrhea, feeding intolerance (poor feeding, vomiting), poor weight gain, or dirty skin color (poor tissue perfusion).

In all cases (diagnosed to have significant hyperbilirubinemia), sex; birth weight; route of delivery; maternal age; gestational age; postnatal age (as hours) on admission; weight on admission; weight loss as percent in comparison with birth weight; abnormal weight loss defined as the loss of body weight more than 7% and 12% on the fourth and seventh days of life, respectively^[@bibr14-1179556517701118]^; feeding pattern; whether there was enclosed hemorrhage; blood groups and Rh types in mother-infant pairs; hemoglobin and hematocrit levels; number of white blood cells; ratio of immature-to-total neutrophils on peripheral blood smear; results of reticulocyte count and direct antiglobulin test; level of C-reactive protein; serum total and direct bilirubin levels measured with colorimetric method (diazotized sulfanilic acid reaction; Roche Diagnostics GmbH, Mannheim, Germany); renal function tests (blood urea nitrogen and creatinine); free T~4~ and thyroid-stimulating hormone (TSH) levels; results of blood gases examination, if needed; glucose-6-phosphate dehydrogenase levels; whether there was any growth in urine culture and types and amounts of microorganism(s); and results of microscopic examination of urine (whether pyuria was present or not) were recorded. No further detailed tests were done toward demonstrating the etiology of hyperbilirubinemia in newborns with both significant hyperbilirubinemia and UTI.

Bladder catheterization was performed with aseptic technique after feeding and fixation of the infant. In all cases in whom phototherapy was started, serum total and direct bilirubin levels were measured at the 24th hour of phototherapy to evaluate the response to treatment and make the decision to stop treatment, and decrease in serum total bilirubin levels at the 24th hour of phototherapy was recorded as percentage decrease. Urine samples were sent immediately to microbiology laboratory for standard quantitative culture, and growth of single type microorganism on culture medium with an amount of at least 1000 CFU/mL was accepted as UTI.^[@bibr15-1179556517701118]^ Renal ultrasonography was performed on all newborns with UTI, and voiding cystoureterography (after obtaining a sterile urine culture, approximately 1 month after the diagnosis) and dimercaptosuccinic acid scintigraphy (3 months after the diagnosis) were performed on those with any abnormality on renal ultrasonography.

In the initial analysis of the data prevalence of UTI as the cause of significant hyperbilirubinemia was determined. Later on, newborns with significant hyperbilirubinemia but without UTI and newborns with both significant hyperbilirubinemia and UTI were classified as group I and group II, respectively, and these groups were compared regarding demographic, laboratory, radiological, and microbiological characteristics.

SPSS 18.0 program was used in statistical analysis of data. Kolmogorov-Smirnov test was used in determining normal distribution. Nominal values, such as sex, route of delivery, presence or absence of pyuria, and feeding pattern, were compared with χ^2^ and Fisher exact χ^2^ tests. Of continuously variable parameters, gestational age, age on admission, and serum direct (conjugated) bilirubin levels were compared with Mann-Whitney *U* test, and maternal age, birth weight, weight on admission, levels of serum total bilirubin, free T~4~, TSH, hemoglobin, hematocrit, and serum bilirubin at 24th hour were compared with independent sample *t* test. Decrease in serum total bilirubin level at 24th hour calculated as percent was compared between the groups using Mann-Whitney *U* test. Values were given as mean ± SD. A *P* value of ≤.05 was considered statistically significant.

Results {#section7-1179556517701118}
=======

The study was started with 188 newborns. However, parents of 12 newborns did not want to participate in the study, 21 newborns were excluded as they had exclusion criteria, and a total of 155 newborns with significant hyperbilirubinemia were finally included in the study during the study period. Mean gestational age and age on admission of these newborns were 37.7 ± 1.5 weeks and 126.6 ± 58.8 hours, respectively. Mean birth weight and weight on admission were 3141.1 ± 499.7 and 2978.3 ± 462.1 g, respectively, and weight loss on admission was −5.11 ± 3.64%. On admission, serum total and direct bilirubin levels were 18.55 ± 2.98 and 0.56 ± 0.15 mg/dL, respectively, and serum total bilirubin level at the 24th hour of phototherapy was 9.03 ± 1.54 mg/dL with a 51.2 ± 3.96% decrease. In all these cases, phototherapy was administered, and no other treatment modalities, such as exchange transfusion and intravenous immunoglobulin administration, were needed.

Urinary tract infection was detected in 26 (16.7%) of the 155 newborns included. Of these, 3 (11.5%) and 23 (88.5%) were women and men, respectively, and causative agents were *Klebsiella* spp. (8 of 26: 30.76%), *Enterococcus* spp. (7 of 26: 26.92%), *Staphylococcus* spp. (6 of 26: 23.07%), *Escherichia coli* (4 of 26: 15.38%), and *Streptococcus* spp. (1 of 26: 3.84%). None of the cases with UTI was circumcised. On ultrasonographic examination, an abnormality was detected in 7 (26.9%) of the 26 newborns diagnosed to have UTI, although most of these were benign in nature; 6 of these 7 newborns were men, and no vesicoureteral reflux of grade ≥3 or renal scar was detected in any of these patients. Demographic and laboratory characteristics of newborns with significant hyperbilirubinemia and diagnosed to have UTI are given in [Table 1](#table1-1179556517701118){ref-type="table"}, and characteristics of patients with renal ultrasonographic abnormality are given in the second half of the table.

###### 

Demographic and laboratory characteristics of newborns with significant hyperbilirubinemia and diagnosed to have urinary tract infection (n = 26).

![](10.1177_1179556517701118-table1)

  Case   Age ON admission, h   Birth weight, g   Sex      Growing microorganism on urine culture and its amount, CFU/mL   SERUM TOTAL BILIRUBIN, MG/DL^[a](#table-fn1-1179556517701118){ref-type="table-fn"}^   Abnormality on renal ultrasonography
  ------ --------------------- ----------------- -------- --------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------
  2      126                   2910              Male     100 000 *Staphylococcus*                                        19.9                                                                                  Normal
  6      162                   2110              Male     50 000 *Klebsiella* spp.                                        15.2                                                                                  Normal
  7      120                   3260              Female   10 000 *Escherichia coli*                                       23.9                                                                                  Normal
  8      78                    3260              Male     100 000 *Enterococcus*                                          17.4                                                                                  Normal
  10     79                    3450              Male     10 000 *E coli*                                                 24.1                                                                                  Normal
  11     236                   2500              Male     100 000 *E coli*                                                18                                                                                    Normal
  12     122                   3150              Male     20 000 *Staphylococcus*                                         20                                                                                    Normal
  14     48                    3770              Male     100 000 *Staphylococcus*                                        17.9                                                                                  Normal
  15     96                    3370              Male     50 000 *Enterococcus*                                           19.6                                                                                  Normal
  16     152                   3850              Male     50 000 *Klebsiella* spp.                                        19.9                                                                                  Normal
  17     107                   4000              Male     100 000 *Staphylococcus*                                        21.4                                                                                  Normal
  18     54                    3700              Female   30 000 *Streptococcus*                                          13.4                                                                                  Normal
  19     162                   4160              Male     30 000 *Enterococcus*                                           24.9                                                                                  Normal
  20     216                   2000              Male     100 000 *Klebsiella* spp.                                       20.6                                                                                  Normal
  22     76                    3200              Male     100 000 *Enterococcus*                                          20.2                                                                                  Normal
  23     176                   3600              Male     100 000 *Klebsiella* spp.                                       17.3                                                                                  Normal
  24     98                    3200              Male     50 000 *Klebsiella* spp.                                        23                                                                                    Normal
  25     66                    3530              Male     100 000 *Staphylococcus*                                        16.1                                                                                  Normal
  26     144                   3150              Male     100 000 *Enterococcus*                                          19.5                                                                                  Normal
  1      239                   2830              Female   30 000 *Klebsiella* spp.                                        20.7                                                                                  Left pelviectasis
  3      99                    3680              Male     100 000 *Klebsiella* spp.                                       18.4                                                                                  Unilateral cortical cyst
  4      168                   3240              Male     100 000 *Enterococcus*                                          24.7                                                                                  Left pelviectasis
  5      121                   4170              Male     100 000 *Klebsiella* spp.                                       20.6                                                                                  Minimal dilatation in bilateral renal pelvises
  9      96                    3060              Male     100 000 *E coli*                                                23.3                                                                                  Left hydronephrosis
  13     119                   3900              Male     30 000 *Staphylococcus*                                         23.7                                                                                  Bilateral pelviectasis
  21     40                    3690              Male     100 000 *Enterococcus*                                          18.4                                                                                  Right renal solid cyst

1 mg/dL bilirubin = 17.1 µmol/L bilirubin.

Detailed clinical signs and symptoms, laboratory abnormalities, and treatment modalities of newborns with both significant hyperbilirubinemia and UTI are given in [Table 2](#table2-1179556517701118){ref-type="table"}.

###### 

Detailed clinical signs and symptoms, laboratory abnormalities, and treatment modalities of newborns with both significant hyperbilirubinemia and urinary tract infection (n = 26).

![](10.1177_1179556517701118-table2)

  Case   Complaints (of the parents) and positive clinical signs and symptoms   Positive laboratory abnormalities                                                                Repeat (control) culture (urine/blood)^[a](#table-fn3-1179556517701118){ref-type="table-fn"}^   Treatment
  ------ ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------- ---------------------
  1      Fever, jaundice                                                        Blood culture + pyuria (46 white blood cell per HPF), high serum bilirubin level (20.7 mg/dL)    Sterile                                                                                         Teicoplanin IV
  2      Feeding intolerance, jaundice                                          High BUN/Cre (50 mg/dL/0.7 mg/dL), high serum bilirubin level (19.9 mg/dL)                       Sterile                                                                                         Cefotaxime IV + FR
  3      Jaundice                                                               High serum bilirubin level (18.4 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  4      Jaundice                                                               Pyuria (22 white blood cell per HPF), high serum bilirubin level (24.7 mg/dL)                    Sterile                                                                                         Teicoplanin IV
  5      Jaundice                                                               High serum bilirubin level (20.6 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  6      Feeding intolerance, jaundice                                          High serum bilirubin level (15.2 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  7      Jaundice                                                               High serum bilirubin level (23.9 mg/dL)                                                          Sterile                                                                                         Teicoplanin IV
  8      Fever, jaundice                                                        High CRP level (24.1 mg/dL), high *I*/*T* ratio (0.4), high serum bilirubin level (17.4 mg/dL)   Sterile                                                                                         Teicoplanin IV
  9      Jaundice                                                               High serum bilirubin level (23.3 mg/dL)                                                          Sterile                                                                                         Teicoplanin IV
  10     Poor weight gain, jaundice                                             High BUN/Cre (60 mg/dL/0.8 mg/dL), high serum bilirubin level (24.1 mg/dL)                       Sterile                                                                                         Cefotaxime IV + FR
  11     Jaundice                                                               High serum bilirubin level (18 mg/dL)                                                            Sterile                                                                                         Teicoplanin IV
  12     Jaundice                                                               High serum bilirubin level (20 mg/dL)                                                            Sterile                                                                                         Teicoplanin IV
  13     Lethargy + irritability, jaundice                                      High serum bilirubin level (23.7 mg/dL)                                                          Sterile                                                                                         Teicoplanin IV
  14     Jaundice                                                               High serum bilirubin level (17.9 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  15     Jaundice                                                               High serum bilirubin level (19.6 mg/dL)                                                          Sterile                                                                                         Teicoplanin IV
  16     Diarrhea, jaundice                                                     High serum bilirubin level (19.9 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  17     Jaundice                                                               High serum bilirubin level (21.4 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  18     Poor tissue perfusion, jaundice                                        Metabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)                Sterile                                                                                         Teicoplanin IV + FR
  19     Jaundice                                                               High serum bilirubin level (24.9 mg/dL)                                                          Sterile                                                                                         Teicoplanin IV
  20     Jaundice                                                               High serum bilirubin level (20.6 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  21     Jaundice                                                               High serum bilirubin level (18.4 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  22     Fever, jaundice                                                        High CRP level/leukocytosis (44.1 mg/dL/17 800/mm^3^), high serum bilirubin level (20.2 mg/dL)   Sterile                                                                                         Teicoplanin IV
  23     Jaundice                                                               High serum bilirubin level (17.3 mg/dL)                                                          Sterile                                                                                         Cefotaxime IV
  24     Jaundice                                                               High serum bilirubin level (23 mg/dL)                                                            Sterile                                                                                         Cefotaxime IV
  25     Jaundice                                                               Pyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)                    Sterile                                                                                         Teicoplanin IV
  26     Jaundice                                                               High serum bilirubin level (19.5 mg/dL)                                                          Sterile                                                                                         Teicoplanin IV

Abbreviations: BUN, blood urea nitrogen; Cre, creatinine; CRP, C-reactive protein; FR, fluid replacement; HPF, high-power field; *I*/*T*, immature-to-total neutrophils; IV, intravenously.

Cerebrospinal fluid cultures were not required after evaluating the newborn's general condition and other laboratory test results. Repeat (control) urine and blood cultures were obtained after completion of treatment.

Comparison of demographic and laboratory characteristics of newborns with significant hyperbilirubinemia but without UTI (group I) and of newborns with both significant hyperbilirubinemia and UTI (group II) is given in [Table 3](#table3-1179556517701118){ref-type="table"}. There were no statistically significant differences between the 2 groups regarding gestational age, maternal age, age on admission, birth weight, weight on admission, abnormal weight loss, hemoglobin and hematocrit levels, route of delivery, feeding pattern, and sex. However, serum total and direct bilirubin levels and ratio of direct to total bilirubin levels on admission and serum total bilirubin levels at the 24th hour of phototherapy were significantly higher in group II compared with group I (18.25 ± 2.94 vs 20.08 ± 2.99, *P* = .005; 0.54 ± 0.13 vs 0.69 ± 0.22, *P* = .001; 0.02992 ± 0.00702 vs 0.035188 ± 0.01581, *P* = .0024; and 8.83 ± 1.49 vs 10.08 ± 1.42, *P* = .0001, respectively) ([Figure 1](#fig1-1179556517701118){ref-type="fig"}). Decrease in serum total bilirubin level at 24th hour calculated as percent was significantly higher in group I compared with group II (51.55 ± 4.01% vs 49.61 ± 3.43%, *P* = .022) ([Table 3](#table3-1179556517701118){ref-type="table"}; [Figure 2](#fig2-1179556517701118){ref-type="fig"}).

###### 

Comparison of demographic and laboratory characteristics of newborns with significant hyperbilirubinemia but without urinary tract infection (group I) and of newborns with both significant hyperbilirubinemia and urinary tract infection (group II).

![](10.1177_1179556517701118-table3)

  Parameter                                                                                                                                                                    Group I (n = 129)   Group II (n = 26)    *P* value
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- -------------------- -----------
  Gestational age, wk^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                   37.87 ± 1.56        37.85 ± 1.19         .946
  Maternal age, y^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                       28.28 ± 5.0         29.92 ± 3.82         .065
  Age on admission, h^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                   128.48 ± 75.58      127.73 ± 66.63       .963
  Birth weight, g^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                       3131.47 ± 475.63    3336.15 ± 555.38     .054
  Weight on admission, g^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                2987 ± 458.1        3175.38 ± 494.14     .061
  Weight loss on admission as percent (if present)^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                      5.08 ± 3.64         6.08 ± 5.26          .242
  Serum total bilirubin, mg/dL^[a](#table-fn4-1179556517701118){ref-type="table-fn"},[b](#table-fn5-1179556517701118){ref-type="table-fn"}^                                    18.25 ± 2.94        20.08 ± 2.99         .005
  Serum direct bilirubin, mg/dL^[a](#table-fn4-1179556517701118){ref-type="table-fn"},[b](#table-fn5-1179556517701118){ref-type="table-fn"}^                                   0.54 ± 0.13         0.69 ± 0.22          .001
  Ratio of direct to total bilirubin levels^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                             0.02992 ± 0.00702   0.035188 ± 0.01581   .0024
  Serum total bilirubin at the 24th hour of phototherapy, mg/dL^[a](#table-fn4-1179556517701118){ref-type="table-fn"},[b](#table-fn5-1179556517701118){ref-type="table-fn"}^   8.83 ± 1.49         10.08 ± 1.42         .0001
  Decrease in serum total bilirubin at 24th hour as percent                                                                                                                    51.55 ± 4.01        49.61 ± 3.43         .022
  Hemoglobin, g/dL^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                      17.54 ± 2.17        17.3 ± 2.3           .608
  Hematocrit^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                            50.8 ± 6.56         50.1 ± 6.67          .594
  Free T4, ng/dL^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                        1.8 ± 2.74          1.4 ± 0.2            .479
  TSH, µIU/mL^[a](#table-fn4-1179556517701118){ref-type="table-fn"}^                                                                                                           3.75 ± 1.8          3.68 ± 2.12          .868
  Presence of pyuria (present/absent)                                                                                                                                          7/122               3/23                 .223
  Route of delivery (vaginal/cesarean)                                                                                                                                         52/78               10/16                .919
  Sex (female/male)                                                                                                                                                            69/60               3/23                 .000
  Enclosed hemorrhage (present/absent)                                                                                                                                         5/124               2/24                 .33
  Abnormal weight loss (present/absent)                                                                                                                                        7/122               2/24                 .647
  Feeding pattern                                                                                                                                                                                                       
   Breast milk (%)                                                                                                                                                             118 (91.47)         22 (84.61)           
   Formula milk (%)                                                                                                                                                            4 (3.1)             1 (3.84)             .094
   Partially breast milk (%)                                                                                                                                                   7 (5.42)            3 (11.53)            

Values are given as mean ± SD.

1 mg/dL bilirubin = 17.1 µmol/L bilirubin.

![Comparison of serum total bilirubin levels in the study groups.](10.1177_1179556517701118-fig1){#fig1-1179556517701118}

![Comparison of percentage decreases in serum total bilirubin levels at the 24th hour of phototherapy in the study groups.](10.1177_1179556517701118-fig2){#fig2-1179556517701118}

Discussion {#section8-1179556517701118}
==========

Although the pathophysiologic relationship between hyperbilirubinemia and UTI has not exactly been revealed, one of the suggested mechanisms is hemolysis caused by *E coli* and other gram-negative bacteria. Even little hemolysis in the newborn may cause significant hyperbilirubinemia due to immature conjugation mechanisms, and thus, serum bilirubin levels may increase as an alerting sign even in UTIs with mild clinical severity. Conjugated hyperbilirubinemia associated with UTI may be related to cholestasis. Although how UTI causes cholestasis is not well defined, microcirculatory problems in liver and direct bacterial and endotoxin-mediated products are the other suggested mechanisms.^[@bibr16-1179556517701118]^ However, some authors claim that the relationship between UTI and neonatal jaundice is just a coincidence.^[@bibr17-1179556517701118]^

In studies investigating the etiologic role of UTI in neonatal jaundice, the incidence of UTI has been reported between 5.8% and 21%.^[@bibr2-1179556517701118],[@bibr5-1179556517701118],[@bibr6-1179556517701118],[@bibr9-1179556517701118]^ Ghaemi et al^[@bibr9-1179556517701118]^ have reported a 5.8% incidence of UTI in 400 newborns in a prospective study. Garcia and Nager^[@bibr5-1179556517701118]^ have reported a UTI incidence of 7.5% in 160 infants of less than 8 weeks old with no other complaints other than jaundice. Bilgen et al^[@bibr2-1179556517701118]^ have reported a UTI incidence of 8% in 102 infants with jaundice. In their retrospective study, Omar et al^[@bibr6-1179556517701118]^ have reported the highest (21%) incidence in 152 jaundiced infants. In our study, we detected the prevalence of UTI as 16.7% in 155 newborns with early jaundice in whom all other etiologic factors of significant neonatal hyperbilirubinemia were ruled out.

There are various ideas about the profile of microorganisms causing both jaundice and UTI. In a retrospective analysis of 120 asymptomatic jaundiced newborns, the most commonly detected (6 of 15) causative agent was *Klebsiella pneumoniae*.^[@bibr11-1179556517701118]^ In another retrospective study, the most common (5 of 12) causative agent was *E coli* in 217 asymptomatic jaundiced infants.^[@bibr4-1179556517701118]^ In our study, the most commonly isolated agent was *Klebsiella* spp. (8 of 26; 30.7%). However, geographical or environmental factors may contribute to bacteriologic and epidemiologic characteristics of UTI.

In infants with UTI, the prevalence of pyuria has reportedly been 58.3%, 52%, and 33% in 3 different studies, respectively.^[@bibr4-1179556517701118],[@bibr8-1179556517701118],[@bibr11-1179556517701118]^ In our study, pyuria was present in 15.3% of 26 newborns with UTI.

Garcia and Nager^[@bibr5-1179556517701118]^, in their study analyzing the association of neonatal jaundice and UTI, have reported that UTI was present in all the cases who had conjugated hyperbilirubinemia. Singh-Grewal et al^[@bibr18-1179556517701118]^ have detected a stronger association with UTI due to *E coli* and conjugated hyperbilirubinemia compared with that of unconjugated hyperbilirubinemia. In our study, cases with both UTI and significant hyperbilirubinemia had significantly higher conjugated bilirubin levels and higher direct/total bilirubin ratio when compared with cases of group I who had significant hyperbilirubinemia without UTI.

In most of the studies investigating the relationship between UTI and neonatal jaundice, male sex was a significant risk factor compared with female sex in the neonatal period.^[@bibr8-1179556517701118],[@bibr9-1179556517701118],[@bibr19-1179556517701118],[@bibr20-1179556517701118]^ In accordance with these studies reported, most of the cases (23 of 26) with both UTI and significant hyperbilirubinemia in our study were men. Ghaemi et al^[@bibr9-1179556517701118]^ have reported that 60% of their male cases with UTI were not circumcised, and Singh-Grewal et al^[@bibr18-1179556517701118]^ have reported that circumcision significantly reduces the risk of UTI. In another study, it has been reported that a high uropathogenic bacteria colonization is observed in uncircumcised newborns, and this increases UTI risk 10-fold.^[@bibr21-1179556517701118]^ As all the newborns in our study were uncircumcised, we could not make a comparison regarding this. However, it has been well demonstrated that newborn circumcision results in a 9.1- to 9.9-fold decrease in incidence of UTI during the first year of life.^[@bibr22-1179556517701118],[@bibr23-1179556517701118]^

Garcia and Nager^[@bibr5-1179556517701118]^ have reported that infants whose jaundice presents after 8 days of life have UTI very likely. In our study, jaundice had occurred in 84.6% of cases in the first 7 days of life. Similarly, Bilgen et al^[@bibr2-1179556517701118]^ have reported that most of their cases developed jaundice after the seventh day of life. This study differs from most of the other studies published as newborns with early-onset (≤7 days) jaundice were studied predominantly.

Ghaemi et al^[@bibr9-1179556517701118]^ have reported that infants fed formula milk had a significantly higher risk of UTI compared with infants fed breast milk. Chen et al^[@bibr4-1179556517701118]^ have also reported similar results. In this study, we did not detect a significant difference between the groups with and without UTI regarding feeding pattern.

In their study comparing jaundiced infants with and without UTI, Shahian et al^[@bibr11-1179556517701118]^ have detected no significant differences regarding serum bilirubin levels. Some other studies have reported significantly lower serum bilirubin levels in newborns with prolonged jaundice and UTI compared with those without UTI.^[@bibr3-1179556517701118],[@bibr24-1179556517701118]^ In our study, however, serum bilirubin levels both on admission and at the 24th hour of phototherapy were statistically significantly higher in newborns with UTI and jaundice compared with those with jaundice but without UTI.

In our study design, we tested the efficacy of phototherapy by measuring and comparing the serum bilirubin levels at 24th hour. We found that response to phototherapy in terms of serum bilirubin decrease was lower in newborns with both UTI and jaundice compared with those with jaundice but without UTI. Poor phototherapy response similar to that observed in hemolytic hyperbilirubinemias is interesting; this may have also resulted from statistically significantly increased serum direct bilirubin levels and direct to total bilirubin ratio, and thus, the possibility of UTI should be considered in jaundiced (especially conjugated) newborns who do not respond to phototherapy well or have a prolonged duration of phototherapy treatment.

As a conclusion, UTI should be routinely investigated in early (≤10 days) idiopathic neonatal jaundice in which all other etiologic factors of neonatal hyperbilirubinemia are ruled out, and the presence of UTI should be considered in case of a poor phototherapy response in cases receiving phototherapy.
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